LANXESS expands capacity of microbial active ingredient Preventol CMK by 50 percent
Long-term trend towards more disinfection
LANXESS is expanding its production capacity for the active ingredient Preventol CMK (chlorocresol) at the Krefeld-Uerdingen, Germany, site by around 50 percent in response to the continuing strong demand for disinfectants and industrial preservation. The specialty chemicals company has invested a single-digit million euro amount for the expansion, which will be completed still in the first quarter of 2022.

Specialty chemicals company LANXESS is expanding its production capacity for the active ingredient Preventol CMK at the Krefeld-Uerdingen, Germany, site by around 50 percent due to strong demand for disinfectants.
LANXESS
LANXESS markets Preventol CMK as a registered active ingredient for disinfection and preservation and also uses it in its own formulations marketed under the known Preventol and Virkon brands. A rapidly growing area of application is disinfectants in the animal and human sectors. Demand for these products has risen significantly in recent years due to the African swine fever, the avian influenza and the Corona pandemic, among other things.
“With the additional capacities, we remain a reliable partner for our customers and can continue to meet the increased demand for Preventol CMK in the disinfection industry,” said Matthias Arnold, head of the Actives & Disinfection business line at LANXESS’ Material Protection Products business unit. “For disinfectants, we expect sustained high demand even after the Corona pandemic due to an increased hygiene awareness.”
In agricultural businesses, disinfectants based on Preventol CMK help contain the spread of diseases and contribute to the reduction of antibiotics in animal husbandry. The topic of biosecurity is also gaining in importance worldwide due to increasing population and meat consumption, leading to a sustained increase in demand for disinfectants. In the field of human health, disinfectants based on Preventol CMK can be used in hospitals, for example, but also in the household application segment.
LANXESS is the world’s largest producer of chlorocresol and provides regulatory support for the active ingredient in all major biocide markets, such as in Europe under the Biocidal Products Regulation BPR or in the USA with the Environmental Protection Agency EPA.
Increasing requirements in industrial preservation
LANXESS also expects strong market growth in the field of industrial preservation. The CMK-based Preventol products from LANXESS have a very broad and balanced spectrum of activity against molds, bacteria and yeasts - even in highly microbiologically contaminated media. This makes them interesting for numerous applications - especially in leather preservation and construction.
“Our Preventol CMK-based products meet the stringent regulatory requirements worldwide. The expansion will enable us to satisfy the strong demand for these products also in the future,” said Oliver Kretschik, head of the Biocides business line at the Material Protection Products business unit.
In the construction industry, CMK-based Preventol products can replace products containing formaldehyde. In the leather industry, they meet both high technical requirements and rising industry standards in terms of sustainability and toxicity.
Organizations
Other news from the department business & finance
These products might interest you

Pharmaceutical Substances by Thieme Verlag
Look up Industrial Syntheses of 2,600 APIs
Your tool for Syntheses, Patents and Applications – Pharmaceutical Substances

KNAUER IJM NanoScaler by KNAUER
Efficient formulation of lipid nanoparticles for RNA-based therapies
Optimise drug encapsulation from 1 ml to hundreds of millilitres with minimal drug input

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.